home / stock / cyad / cyad news

CYAD News and Press, Celyad SA From 12/15/20

Stock Information
Company Name: Celyad SA
Stock Symbol: CYAD
Market: NASDAQ
Menu
CYAD CYAD Quote CYAD Short CYAD News CYAD Articles CYAD Message Board
Get CYAD Alerts

News, Short Squeeze, Breakout and More Instantly...
CYAD - Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC

Preliminary data from the expansion cohort are expected during first half 2021 MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of ch...
CYAD - Celyad Oncology slips 5% after suspending developmemt of CYAD-01 in early-stage THINK trial

Celyad Oncology (CYAD) announces updates from its shRNA-based anti-B cell maturation antigen ((BCMA)) allogeneic CAR T candidate, CYAD-211, and autologous NKG2D receptor-based CAR T candidates, CYAD-01 and CYAD-02. CYAD-211 and IMMUNICY-1 Phase 1 Trial Update:IMMUNICY-1 will evaluate the safe...

CYAD - Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

First patient dosed in the CYAD-211 Phase 1 IMMUNICY-1 trial. Preclinical results for CYAD-211 for multiple myeloma showed robust antitumor activity with no demonstrable evidence of G raft-versus- H ost D isease Company discontinues th...

CYAD - Dosing underway in Celyad Oncology's early-stage CYAD-211 study for multiple myeloma

The first patient has been dosed in Celyad Oncology's (CYAD) Phase 1 IMMUNICY-1 trial of CYAD-211, a novel, short hairpin RNA (shRNA)-based anti-B-cell maturation antigen candidate for the treatment of relapsed/refractory multiple myeloma (r/r MM).The trial will evaluate multiple dose levels ...
CYAD - Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma

Preliminary data from the Phase 1 trial are expected first half 2021 Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211 MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad O...

CYAD - Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit

MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Filippo Pet...

CYAD - Celyad Oncology reports Q3 results

Celyad Oncology (CYAD): Q3 Treasury position of €20M.Press Release For further details see: Celyad Oncology reports Q3 results

CYAD - Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights

Established a clinical trial collaboration with MSD to evaluate CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC Expect to initiate the expansion cohort of the Phase 1 alloSHRINK trial for CYAD-101 in mCRC patients following FOLFIRI preconditioning chemotherapy...

CYAD - Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition

Three accepted abstracts will be presented virtually in a pre-recorded poster session MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and developmen...

CYAD - Celyad Oncology Announces November 2020 Investor Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company...
Previous 10 Next 10